Meningococcal ACWY Conjugate Vaccine | Menactra - Sanofi

Advanced Meningococcal Disease Immunization (MCV4)

When protecting patients—from infants to adults—against the rapid-onset and life-threatening impacts of invasive meningococcal disease (including meningitis and meningococcemia), healthcare providers require a comprehensive and highly reliable clinical intervention. The Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (commercially recognized as Menactra) provides targeted, active immunization designed strictly for intramuscular (IM) administration. Manufactured by Sanofi Pasteur, a global pioneer in advanced immunology, these single-dose vials ensure the powerful clinical performance necessary for critical vaccination protocols and outbreak responses.

Why Choose Menactra for Clinical Immunization?

Shielding patients from Neisseria meningitidis requires targeted serogroup coverage. Clinical specialists rely on Menactra because its advanced quadrivalent formulation protects against four major disease-causing serogroups (A, C, Y, and W-135). By utilizing conjugate vaccine technology—covalently binding the meningococcal capsular polysaccharides to a highly immunogenic diphtheria toxoid carrier protein—Menactra ensures a robust, T-cell-dependent immune response. This establishes a stronger and longer-lasting immune memory compared to traditional, non-conjugated polysaccharide alternatives.

Key Product Specifications & Clinical Benefits

Quadrivalent Broad Coverage: Delivers active protection against four major serogroups of meningococcal bacteria: A, C, Y, and W-135.

Advanced Carrier Protein: Conjugated to Diphtheria Toxoid to significantly enhance the patient's immune response and establish long-lasting cellular memory.

Clinical Supply Pack: Conveniently supplied as a box containing 5 single-dose sterile vials, providing an efficient supply for busy immunization clinics and hospitals.

Targeted Intramuscular Delivery: Formulated strictly for Intramuscular Injection, guaranteeing optimal absorption and systemic immune activation.

Essential Storage & Usage Guidelines

Maintaining the delicate biological integrity of this conjugate vaccine is absolutely vital for its clinical efficacy.

Strict Cold Chain: Store the vials strictly in a refrigerator between 2°C to 8°C (36°F to 46°F).

Do Not Freeze: Freezing will irrevocably destroy the active vaccine structure. Discard immediately if the vaccine has been frozen.

Preparation: Protect from light. Keep the vials in the original carton until ready for use. Draw the exact 0.5 mL dose using a sterile syringe immediately prior to injection.

Important Notice: Menactra is a Prescription Drug. It must be prescribed, handled, and administered strictly by a Registered Medical Practitioner in a clinical or hospital setting. Keep all medicines safely out of the reach of children.